Iszy Shirley

*** All Eyes On Biotech *** The biotech sector is booming, driven by a wave of pipeline successes and strategic acquisitions. In 2023 alone, the global biotech market reached $833.34 billion, with a projected CAGR of 15.83% from 2024 to 2029. The EMEA region is a major player, with European biotech companies raising over €10 billion in venture capital in the past year. Major shifts on the market; more specifically, M&A activity, with biotech acquisitions hitting a record high. Major deals like the $39 billion acquisition of Alexion by AstraZeneca and Novartis's continued expansion through targeted acquisitions highlight the industry's versatility. This growth is not just numbers; it’s about innovative therapies, life-saving treatments, and groundbreaking research. It's an exciting era for biotech, with major opportunities for both companies and our local network. Thrilled to be part of this evolving landscape, connecting top talent with pioneering organizations. #Biotech #Pharma #Growth #Innovation #Recruitment #Healthcare #LifeSciences #Switzerland #CareerOpportunities

32

Profluent is using protein language models to design new gene editing systems. The company has open sourced their first AI-designed gene editor, OpenCRISPR-1, to help accelerate progress in this space. “Attempting to edit human DNA with an AI-designed biological system was a scientific moonshot. our success points to a future where AI precisely designs what is needed to create a range of bespoke cures for disease. To spur innovation and democratization in gene editing, with the goal of pulling this future forward, we are open-sourcing the products of this initiative.”” - Ali Madani, Profluent co-founder and Chief Executive Officer. https://lnkd.in/dVWK_wrE #AIprotein #proteindesign #CRISPR #geneediting #artificialintelligence #biotech

18

A great historical review of epigenetics and cancer. Always great to see some of the founders of the relatively new field of epigenetics (circa 2000's) and how they laid the groundwork. #biomodal, #epigenetics #epigenomics #cancer #oncology

11

𝐈𝐧 𝐭𝐡𝐞 𝐥𝐚𝐬𝐭 𝐟𝐞𝐰 𝐰𝐞𝐞𝐤𝐬 𝐈'𝐯𝐞 𝐧𝐨𝐭𝐢𝐜𝐞𝐝 𝐦𝐚𝐧𝐲 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐦𝐚𝐤𝐢𝐧𝐠 𝐝𝐞𝐚𝐥𝐬 𝐭𝐨 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐭𝐡𝐞𝐢𝐫 𝐩𝐢𝐩𝐞𝐥𝐢𝐧𝐞𝐬 𝐚𝐧𝐝 𝐡𝐞𝐫𝐞 𝐚𝐫𝐞 𝐚 𝐟𝐞𝐰 𝐭𝐡𝐚𝐭 𝐬𝐭𝐨𝐨𝐝 𝐨𝐮𝐭 𝐭𝐨 𝐦𝐞... 📍Ipsen and the China-based Biotech Foreseen Biotechnology, have a global licencing agreement for a preclinical ADC - an undisclosed tumor-associated antigen that was discovered using Foreseen's AI and translational proteomics screening platforms. Ipsen will take on the preparations for a Ph1 trial starting with IND applications 📍Eli Lilly and Company plans to pay $3.2 billion in cash for Morphic Therapeutic - it marks the first biotech acquisition that Lilly has disclosed this year! As the autoimmune space continues to bubble up pharma interest, it'll be interesting to see what will follow with the oral integrin drugs for chronic diseases that Morphic currently works on 📍Thermo Fisher Scientific have closed the acquisition of Olink - a leading provider of next-generation proteomics solutions. Are there any that I've missed worth sharing? ARTO

16

📡 𝐄𝐧𝐳𝐞𝐧𝐞 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐚 $𝟓𝟎 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 𝐧𝐞𝐰 𝐬𝐢𝐭𝐞 💥 Enzene Biosciences Ltd will be opening a new discovery site in response to the rapidly growing industry demands! ⬇ Learn more in the below for a better understanding into there peptides industry!

145

"Spatial molecular profiling (Spatial Omics) technologies are powerful microscopes that allow scientists to study tissues in great detail, by revealing the exact locations of individual biological molecules in cells, as well as the arrangement of cells in tissues. This helps them understand how cells come together in tissues to perform their normal physiological functions, and also how they behave (or misbehave) in diseases such as cancer, autism or infectious diseases such as COVID-19. This understanding is essential for more accurate diagnosis and tailored treatment of patients, as well as the discovery of new drugs." #omics #biology #spatial #technology #bioinformatics #artificialintelligence #diagnostics

5

Veranova'𝘀 $𝟯𝟬𝗠 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗘𝘅𝗽𝗮𝗻𝗱𝘀 𝗔𝗗𝗖 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗖𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 This investment aims to enhance the site’s (Devens, MA) existing capabilities and address the increasing demand for strong US-based capacity for ADCs and other potent small molecules. #CDMO #ContractDevelopment #ContractManufacturing

26

🧬 Exciting opportunities in Synthetic Biology for Investors & Entrepreneurs! 🚀 Synthetic Biology start-ups are on the rise, offering a wealth of potential for those keen on innovation and growth in the biotech industry. Here's why you should take notice: 🔍 **Emerging Market**: Synthetic Biology presents a rapidly growing market with vast untapped potential, attracting both investors and entrepreneurs looking to make their mark in groundbreaking science. 💡 **Innovative Solutions**: These start-ups are at the forefront of creating novel solutions to some of society's most pressing challenges, ranging from sustainable energy to healthcare advancements. 📈 **Market Growth**: With the global Synthetic Biology market projected to reach $20 billion by 2025, there's no denying the immense growth opportunities awaiting those who jump on this bandwagon early. Curious to explore more about this cutting-edge field? Share your thoughts on the immense possibilities Synthetic Biology brings for both investors and entrepreneurs in the comments below! Let's dive into the future of biotech together. 🌟 #SyntheticBiology #BiotechInnovation #InvestmentOpportunities

3

🤝 Cell Therapy Collaboration Alert 🤝 Shinobi Therapeutics is making waves by teaming up with industry giant Panasonic and Japans Kyoto University. This partnership marks a pivotal moment in the history of iPS cell-derived therapies. 🔄 𝐇𝐢𝐬𝐭𝐨𝐫𝐲 𝐦𝐞𝐞𝐭𝐬 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Kyoto University, where the first mouse iPS cells were created in 2006, joins forces with Shinobi and Panasonic. 🔬 𝐖𝐡𝐚𝐭'𝐬 𝐭𝐡𝐞 𝐩𝐥𝐚𝐧? Develop a cutting-edge manufacturing platform for iPS-T cell therapies, aiming for higher efficiency and lower costs. 🛠️ 𝐏𝐚𝐧𝐚𝐬𝐨𝐧𝐢𝐜'𝐬 𝐫𝐨𝐥𝐞: Creating a closed-system manufacturing device to optimize Shinobi's iPS-T cell platform, leveraging Kyoto University's research. 🚀 𝐏𝐡𝐚𝐬𝐞 𝐨𝐧𝐞 𝐭𝐚𝐫𝐠𝐞𝐭: Revealing the initial manufacturing prototype by April next year. 👩‍🔬 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐀𝐜𝐭𝐢𝐨𝐧: This collaboration signals a major step forward in the field of cell therapy, promising better accessibility and affordability for patients worldwide. 𝐂𝐡𝐞𝐜𝐤 𝐨𝐮𝐭 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐡𝐞𝐫𝐞 🔽 #celltherapy #celltherapymanufacturing https://lnkd.in/eQYfWRqU

17

Major upgrade to #AlphaFold! The latest tool, AlphaFold 3, AI models how proteins interact with other molecules — but Google DeepMind restricts access to the tool. The latest version of AlphaFold, described on 8 May in Nature (https://lnkd.in/gsmgmJiv) gives scientists the ability to predict the structures of proteins during interactions with other molecules. But whereas DeepMind made the 2021 version of the tool freely available to researchers without restriction, AlphaFold3 is limited to non-commercial use through a DeepMind website. https://lnkd.in/gmKzM6zV

9

🌍 Stay up-to-date with the latest product launches in the field! Here are some recent highlights: 🔬 Integrated DNA Technologies introduces Avian Influenza Type A (H5) Primers and Probe Set for identifying the H5N1 virus. 🧬 GT Molecular launches a multiplex RT-PCR panel detecting eight key KRAS G12-G13 mutations with high sensitivity. 🔎 Illumina's Dragen v4.3 software offers accurate multigenome mapping, machine learning advancements, and more for genomics research. 🔬 QIAGEN updates QCI Interpret software to enhance clinical reporting for NGS labs, including new variant assessment features. 🧪 Bio-Rad Laboratories introduces quality controls for group B Streptococcus molecular assays for precise testing. 🔬 SPT Labtech launches Mosquito Gen3, a compact liquid handling platform for NGS, supporting multichannel pipetting with high precision. 🔬 Navinci Diagnostics releases automated in situ proximity ligation assays for Leica Biosystems Bond Rx platform for protein interaction and immune checkpoint studies. Stay informed about these cutting-edge advancements! #ProductLaunches #ScienceAndTechnology 🚀

8

🧬 Earnings Calls 🧬 Exciting times for the Omics industry as we see companies announce Q1 results, dictating an uplift in the market - all eyes on the Genomics market leader Illumina for their earnings call later today. So far some announcements include: NeoGenomics Laboratories: First quarter revenue increased 14% to $156m 10x Genomics: Increase of 5% to $141m - driven by Spatial revenue PacBio: Prelims suggest that revenue has maintained parity with the same period (Earnings call 9th May) What are your thoughts?

20

𝗧𝗼𝗽 𝟮𝟬 𝗗𝗿𝘂𝗴𝘀 𝗼𝗳 𝟮𝟬𝟮𝟯 𝗯𝘆 𝗥𝗲𝘃𝗲𝗻𝘂𝗲💉💊 Interesting to see this displayed in this way. What do you think this year will look like? 𝗪𝗵𝗼 𝘄𝗶𝗹𝗹 𝘁𝗮𝗸𝗲 𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝘁𝗼𝗽 𝘀𝗽𝗼𝘁? thanks to Anis for putting this together in a visual representation #PharmaNews #CDMO #Biotech #MasonHarding Link to full report in the comment section.

86

3 Comments

🔍 Industry Insight: Trends Shaping the Future of Biotech Recruitment 🔍 The biotech industry is evolving rapidly, and so are its hiring needs. Here are some key trends we're observing: Increased Demand for Strategic Marketing: As biotech companies reposition themselves after what has been an interesting period over the last year, they want to focus on direction and align it with what the market is asking for. Remote Work: Flexible working arrangements are becoming more of a norm, yet many companies still want staff located close enough to the office to get in when needed. Focus on Soft Skills: Collaboration and adaptability are critical as teams work cross-functionally to innovate and solve complex problems. Are you prepared for these changes? Let's discuss how you can stay ahead in this dynamic field. 🚀 #Biotech #Recruitment #IndustryTrends #Hiring

5

🔬 Exciting News in Protein Research! 🔬 Fluidic Sciences has acquired the innovative technology developed by Fluidic Analytics and is relaunching their groundbreaking platform! 🎉 🌟 Key Highlights: 🔹 Technology Relaunch: Fluidic Sciences is bringing back the Fluidity One-M instrument, originally launched in 2018. 🔹 Microfluidic Diffusional Sizing (MDS): This cutting-edge technology allows for precise protein analysis, leveraging laminar flow at the microfluidic scale to determine protein size and interactions. 🔹 Applications: The relaunch targets biopharmaceutical research areas including membrane protein characterization, vaccine responses, monoclonal therapeutic antibodies, and targeted protein degradation. 💡 Innovative Approach: The Fluidity One-M runs two fluid streams side by side, with proteins moving between them by diffusion. This enables accurate measurement of protein size and aggregation, revolutionizing protein research. 🔬 Scientific Leadership: Sean Devenish, formerly head of R&D at Fluidic Analytics, is now Chief Scientist at Fluidic Sciences, ensuring continuity and expertise. 💬 Leadership Insight: "Thanks to everyone involved in the refounding activity, this is now ready to be a truly successful global business," said Mark Gilligan, board member at Fluidic Sciences. 📈 Early Adoption Program: An early adoption program with introductory pricing is available through 2024. Don't miss the chance to integrate this powerful technology into your research! #ProteinResearch #Biotechnology #FluidicSciences #FluidityOneM #Microfluidics #Biopharmaceuticals #Innovation #Research #TechRelaunch #ScientificBreakthrough #BiotechNews

9

1 Comment

🧬𝐂𝐚𝐧 𝐁𝐫𝐢𝐝𝐠𝐞 𝐑𝐍𝐀 𝐛𝐞 𝐚 𝐍𝐞𝐰 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫 𝐢𝐧 𝐆𝐞𝐧𝐞 𝐄𝐝𝐢𝐭𝐢𝐧𝐠?🧬 CRISPR revolutionized biomedical science by allowing precise gene edits, but it has limitations with large DNA segments and risks unintended damage. A recent discovery by Patrick Hsu and his team at the Arc Institute offers a potential solution, Bridge RNA. 𝘋𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 Bridge RNA, found in bacteria, recognizes two DNA strands simultaneously: the target and the new gene. It recruits an enzyme called recombinase to execute precise edits without breaking both DNA strands. This method stems from studying the bacterial transposable element IS110, which can be programmed to insert specific DNA sequences. 𝘈𝘥𝘷𝘢𝘯𝘵𝘢𝘨𝘦𝘴 𝘖𝘷𝘦𝘳 𝘊𝘙𝘐𝘚𝘗𝘙 Unlike CRISPR, which relies on cell repair mechanisms and risks unintended damage, bridge RNA enables large genetic edits in a single step. It offers more control, as both the target and donor sequences can be specified. 𝘍𝘶𝘵𝘶𝘳𝘦 𝘈𝘱𝘱𝘭𝘪𝘤𝘢𝘵𝘪𝘰𝘯𝘴 Tested in bacteria, the next steps involve adapting bridge RNA for human cells, potential uses include introducing genes into cancer cell therapies, replacing defective genes in inherited conditions, and removing DNA causing neurodegenerative disorders. If successful, bridge RNA could surpass CRISPR, offering safer and more precise gene editing. Exciting things to come..

3

1 Comment

🚀 Breaking New Ground in Spatial Multi-Omics! 🧬 Exciting advancements in #Biotechnology! A team led by Xiaofeng Wu and colleagues has developed MiP-seq (multi-omics in situ pairwise sequencing), a revolutionary method for detecting DNAs, RNAs, proteins, and biomolecules at subcellular resolution. 🌟 Key Highlights: - Enhanced Decoding Capacity: Compared to other methods, MiP-seq boosts decoding capacity while slashing sequencing and imaging costs. 📉 - Comprehensive Detection: Effectively detects gene mutations, allele-specific expression, and RNA modifications. 🧬 - Integration with Advanced Imaging: Compatible with in vivo calcium imaging and Raman imaging, enabling the creation of a spatial multi-omics atlas of mouse brain tissues. 🧠 - Innovative Dilution Strategy: Resolves optically crowded signals during in situ sequencing. 🎨 This high-throughput approach is set to revolutionise the multidimensional analysis of molecular and functional maps of tissues, paving the way for groundbreaking discoveries in cellular functions and disease mechanisms. 🔬 #MultiOmics #MiPseq #BiotechInnovation #SpatialOmics #Genomics #Proteomics #Neuroscience #BiomedicalEngineering #ResearchBreakthrough #ScienceInnovation

2

1 Comment

🧬 𝐑𝐞𝐝𝐒𝐡𝐢𝐟𝐭𝐁𝐢𝐨 𝐥𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐀𝐮𝐫𝐨𝐫𝐚 𝐓𝐗 🔬 𝘙𝘦𝘷𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘪𝘻𝘪𝘯𝘨 𝘙𝘕𝘈 𝘢𝘯𝘥 𝘱𝘳𝘰𝘵𝘦𝘪𝘯 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴 𝘸𝘪𝘵𝘩 𝘶𝘭𝘵𝘳𝘢-𝘴𝘦𝘯𝘴𝘪𝘵𝘪𝘷𝘦 𝘮𝘪𝘤𝘳𝘰𝘧𝘭𝘶𝘪𝘥𝘪𝘤 𝘮𝘰𝘥𝘶𝘭𝘢𝘵𝘪𝘰𝘯 𝘴𝘱𝘦𝘤𝘵𝘳𝘰𝘴𝘤𝘰𝘱𝘺 𝘢𝘯𝘥 𝘵𝘩𝘦𝘳𝘮𝘢𝘭 𝘳𝘢𝘮𝘱𝘪𝘯𝘨 𝘤𝘢𝘱𝘢𝘣𝘪𝘭𝘪𝘵𝘺 RedShiftBio - a leader in innovative biophysical characterization and bioprocess analytical solutions, announces the launch of Aurora TX - the most advances instrument featuring ground-breaking MMS technology, addressing the limitations of existing technologies such as CD and FTIR. Key features of the Aurora TX include: 👉 Ultra-sensitive and highly reproducible structural measurements. 👉 Wide applicability across many therapeutic modalities. 👉 Thermal ramping capability for controlled temperature stress/stability assessments. 👉 Walk-away automation with multiple measurements in a single analysis. 👉 Robust delta software for simplified data collection and interpretation. 👉 New, streamlined optional buffer station that enhances throughput by integrating up to 8 buffers directly into the system during analysis. Tom O'Lenic, CEO at RedShiftBio commented; "𝘈𝘶𝘳𝘰𝘳𝘢 𝘛𝘟 𝘳𝘦𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘴 𝘢 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵 𝘮𝘪𝘭𝘦𝘴𝘵𝘰𝘯𝘦 𝘪𝘯 𝘣𝘪𝘰𝘱𝘩𝘺𝘴𝘪𝘤𝘢𝘭 𝘤𝘩𝘢𝘳𝘢𝘤𝘵𝘦𝘳𝘪𝘻𝘢𝘵𝘪𝘰𝘯 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺. 𝘞𝘪𝘵𝘩 𝘪𝘵𝘴 𝘶𝘯𝘱𝘢𝘳𝘢𝘭𝘭𝘦𝘭𝘦𝘥 𝘴𝘦𝘯𝘴𝘪𝘵𝘪𝘷𝘪𝘵𝘺, 𝘱𝘳𝘦𝘤𝘪𝘴𝘪𝘰𝘯, 𝘢𝘯𝘥 𝘷𝘦𝘳𝘴𝘢𝘵𝘪𝘭𝘪𝘵𝘺, 𝘈𝘶𝘳𝘰𝘳𝘢 𝘛𝘟 𝘦𝘮𝘱𝘰𝘸𝘦𝘳𝘴 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩𝘦𝘳𝘴 𝘵𝘰 𝘶𝘯𝘭𝘰𝘤𝘬 𝘥𝘦𝘦𝘱𝘦𝘳 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘪𝘯𝘵𝘰 𝘣𝘪𝘰𝘮𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘴𝘵𝘳𝘶𝘤𝘵𝘶𝘳𝘦𝘴, 𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘪𝘯𝘨 𝘢 𝘱𝘪𝘰𝘯𝘦𝘦𝘳𝘪𝘯𝘨 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘺 𝘧𝘰𝘳 𝘙𝘕𝘈 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴 𝘢𝘯𝘥 𝘱𝘢𝘷𝘪𝘯𝘨 𝘵𝘩𝘦 𝘸𝘢𝘺 𝘧𝘰𝘳 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘮𝘦𝘯𝘵𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘰𝘧 𝘙𝘕𝘈 𝘢𝘯𝘥 𝘱𝘳𝘰𝘵𝘦𝘪𝘯 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤𝘴." Check out the full article below 👇👇👇 #lifesciences #spectroscopy #rna

7

🚀 Opinion: Chinese CDMOs and US Biopharma PR strike a precarious balance 🌍 As the House Oversight and Accountability Committee marked up the BIOSECURE Act targeting China-based biotech companies like WuXi AppTec and WuXi Biologics, I couldn’t help but draw parallels to an epic Game of Thrones saga. 🐉🦅 In March 2024, WuXi AppTec separated from BIO after the industry trade association changed its stance to support the BIOSECURE Act. Recently, BIO proposed an eight-year decoupling period from China-based biomanufacturing, setting a 2032 deadline for U.S. biopharma companies to sever ties. 🕒⚖️ A floor vote is expected in the next 30 days, with WuXi Biologics intensifying their lobbying efforts. Nearly 20 biopharma and life sciences companies are also registered to lobby, striving to balance advocacy without appearing unpatriotic. 🤝💼 With almost 80% of U.S. biopharma companies linked to China-based CDMOs, this proposed grace period is critical to avoid disruptions. So, how can PR professionals navigate this complex landscape? 🌐🔍 Strategic Communication: Engage with industry associations like BIO to advocate for federal funding, similar to the CHIPS Act’s $200 billion support. 💬💰 Reassurance Through Transparency: CDMOs should prioritize international communications, highlighting their commitment to global markets and high regulatory standards. 📢🌍 Proactive Outreach: Use third-party audits, certifications, and data points to assuage client concerns. Focus on professional platforms like industry publications and LinkedIn. 📄✅ As Lord Varys from Game of Thrones noted, “A small man can cast a large shadow.” Thoughtful, strategic actions can influence outcomes and ensure sustainable growth for the U.S. biopharma industry and China-based CDMOs. 🌟 #Biopharma #PR #BIOSECUREAct #WuXiAppTec #WuXiBiologics #USChinaRelations #CDMO #Biotech #Pharmaceuticals #Legislation #Healthcare #GlobalBusiness #StrategicCommunication

1

1 Comment